Company Overview of N-of-One, Inc.
N-of-One, Inc., a molecular decision support company, provides clinicians with interpretation of molecular test results. It provides disease-specific biological relevance, clinical evidence, associated therapies, and references. The company also interprets next generation sequencing (NGS) of solid and hematological tumors, circulating tumor cells and DNA, copy number analysis, and immunohistochemistry. In addition, it offers PrecisionInsights, a clinical interpretation report for 15-20 gene NGS panels, delivering concise clinical and scientific evidence for each biomarker in the context of the cancer sub type and a list of therapeutic options; and TRIALMATCH, a patient-specific clinical tria...
430 Bedford Street
Lexington, MA 02420
Founded in 2007
Key Executives for N-of-One, Inc.
Chairman and Chief Executive Officer
Founder, President, Chief Medical Officer and Director
Chief Financial Officer and Director
Vice President of Operations
Vice President, Secretary and General Counsel
Compensation as of Fiscal Year 2016.
N-of-One, Inc. Key Developments
Inova Schar Cancer Institute Partners with N-of-One to Support the Launch of Inova’s Molecular Tumor Board
Oct 12 16
N-of-One, Inc. announced a partnership with Inova Schar Cancer Institute to support its molecular tumor board, the first in the DC metro area to invite patient and family participation. ISCI is an international center for advanced cancer care and research. Collaborating with clinical and scientific partners, ISCI conducts genomic and translational research to better understand, predict, prevent, and ultimately, eliminate cancer. As part of its contribution, N-of-One is providing patient-specific clinical interpretation and clinical trial matching for Inova’s in-house next generation sequencing panels and re-interpretation with clinical trial matching of the test results from other commercial diagnostics labs. N-of-One will provide Inova’s cancer specialists with the most relevant treatment options through the analysis of each patient’s unique molecular profile. This includes integrating multiple molecular tests and information from N-of-One’s proprietary database, which in turn, can help identify individualized treatment options. Inova’s molecular tumor board is one of the few to include patients and their families in the board’s discussions. This allows patients to hear the discussion and be directly involved in determining the next steps in their cancer care. N-of-One interprets test results prior to the tumor board meeting, and during the meeting, senior scientists from Inova and N-of-One provide scientific support for questions on the test results and for the assessment of relevant treatment strategies. In addition to treatments, N-of-One can also provide clinical trial selection for patient cases. Currently there are hundreds of open clinical trials for targeted therapies.
N-of-One, Inc. Presents at UBS Genomics 2.0 Summit, Aug-11-2016 11:00 AM
Aug 7 16
N-of-One, Inc. Presents at UBS Genomics 2.0 Summit, Aug-11-2016 11:00 AM. Venue: St. Regis Deer Valley, Park City, Utah, United States. Speakers: Christine M. Cournoyer, Chairman and Chief Executive Officer.
N-Of-One to Supply Admera Health with Clinical Interpretation for the OncoGxOne 64-Gene Oncology Panel
Apr 15 16
N-of-One reported that Admera Health has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne. N-of-One's patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient's molecular tests to therapeutic strategies, including clinical trials. N-of-One noted that the OncoGxOne is a next-generation sequencing panel that detects 64 of the most common mutated genes found in several cancer types. Mutation types detected include single nucleotide variants, insertions and deletions, copy number variants and gene fusions associated with all current FDA approved targeted therapies and multiple registered clinical trials.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 23, 2015